Platinum versus non-platinum chemotherapy regimens for small cell lung cancer

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2008, Pages

  Amarasena, Isuru U ^a   Walters, Julia A E ^b   Wood Baker, Richard ^b   Fong, Kwun ^c  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

^c THE PRINCE CHARLES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; CARBOPLATIN; CHLOROZOTOCIN; CIMETIDINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FOLINATE CALCIUM; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; LOMUSTINE; MAYTANSINE; MESNA; METHOTREXATE; METOCLOPRAMIDE; MITOMYCIN; NIMUSTINE; PACLITAXEL; PROCARBAZINE; TOPOTECAN; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE; VINDESINE; WARFARIN;

ALOPECIA; ANEMIA; APPETITE; AREA UNDER THE CURVE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CINAHL; CLINICAL TRIAL; COCHRANE LIBRARY; CONTINUOUS INFUSION; DRUG MEGADOSE; DRUG WITHDRAWAL; EMBASE; GRANULOCYTOPENIA; HUMAN; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LUNG SMALL CELL CANCER; MEDLINE; META ANALYSIS; MOOD; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; QUALITY OF LIFE; REVIEW; SLEEP; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; WELLBEING;

EID: 55049126744     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006849.pub2     Document Type: Review

References (63)

1. Chahinian 1989{published data only} Chahinian AP, Propert KJ, Ware JH, Zimmer B, Perry MC, Hirsh V, et al.A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. Journal of Clinical Oncol 1989 Aug; 7(8):993-1002.
2. Creech 1982{published data only} Creech RH, Stanley K, Vogl SE, Ettinger DS, Bonomi PD, Salazar O. Phase II study of cisplatin,maytansine, and chlorozotocin in small cell lung carcinoma (EST 2578). Cancer Treatment Reports 1982 Jun; 66(6):1417-9.
3. Eagan 1981{published data only} Eagan RT, Lee RE, Frytak S, Fleming TR, Ingle JN, Creagan ET, et al.An evaluation of low-dose cisplatin as part of combined modality therapy of limited small cell lung cancer. Cancer Clinical Trials 1981;4(3):267-71.
4. Evans 1987{published data only} Evans WK, Feld R, Murray N, Willan A, Coy P, Osoba D, et al.Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada. Annals of Internal Medicine 1987 Oct;107(4):451-8.
5. Farris 1993{published data only} Farris A, Bisail M, Sarobba MG, Sanna G, Scotto T, Valzelli S, et al.Cisplatin-VP16 alternating with cyclophosphamide-epirubicin versus cyclophosphamide-epirubicin-vincristine in small cell lung cancer. Journal of Chemotherapy 1993 Oct;5(5):344- 7.
6. Fukuoka 1986{published data only} Fukuoka M, Takada M, Negoro S, Kusunoki Y, Matsui K, Ryu S, et al.Alternating non-cross resistant chemotherapy for small cell lung cancer. Japanese Journal of Clinical Oncology 1986 Sep;16(3):261-70.
7. Fukuoka 1991{published data only} Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, et al.Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. Journal of the National Cancer Institute 1991 Jun 19;83(12):855-61.
8. Gatzemeier 1994{published data only} Gatzemeier U, Pawel JV, Laumen R, Hossfeld DK, Neuhauss R. Etoposide/vincristine-based chemotherapy with or without carboplatin in extensive-stage small cell lung cancer: a prospective randomized phase III trial. Seminars in Oncology 1994 Jun;21(3 Suppl 6):31-5.
9. Goodman 1990{published data only} Goodman GE, Crowley JJ, Blasko JC, Livingston RB, Beck TM, Demattia MD, et al.Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study. Journal of Clinical Oncology 1990 Jan;8(1):39-47.
10. Greco 2005{published data only} Greco FA, Thompson DS, Morrissey LH, Erland JB, Burris HA, 3rd, Spigel DR, et al.Paclitaxel/ carboplatin/etoposide versus paclitaxel/ topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial. Oncologist 2005 Oct;10(9):728-33.
11. Havemann 1987{published data only} Havemann K, Wolf M, Holle R, Gropp C, Drings P, Manke HG, et al.Alternating versus sequential chemotherapy in small cell lung cancer. A randomized German multicenter trial. Cancer 1987 Mar 15;59(6):1072-82.
12. Jones 1993{published data only} Jones AL, Holborn J, Ashley S, Smith IE. CVM versus ACE in the treatment of small cell lung cancer. Oncology 1993 Nov;50 Suppl 2:10-5.
13. Kanitz 1992{published data only} Kanitz E, Kolaric K, Jassem J, Mechl Z, Pawlicki M, Ringwald G, et al.Randomized phase II trial of high-dose 4′-epi-doxorubicin + cyclophosphamide versus high-dose 4′-epi-doxorubicin + cisplatin in previously untreated patients with extensive small cell lung cancer. Oncology 1992;49(5):327-32.
14. Lyss 2002{published data only} Lyss AP, Herndon JE 2nd, Lynch TJ Jr, Turrisi AT, Watson DM, Grethlein SJ, et al.Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430). Clinical Lung Cancer 2002 Feb;3(3):205-10; discussion 11-2.
15. Postmus 1992{published data only} Postmus PE, Splinter TA, Palmen FM, Carney DN, Festen J, Burghouts JT, et al.Comparison of two carboplatin-containing regimens with standard chemotherapy for small cell lung cancer in a randomised phase II study. The EORTC Lung Cancer Cooperative group. European Journal of Cancer 1992;28(1):96-100.
16. Postmus 1996{published data only} Postmus PE, Scagliotti G, Groen HJ, Gozzelino F, Burghouts JT, Curran D, et al.Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: an EORTC Phase III trial. European Journal Cancer 1996 Aug;32A(9):1498-503.
17. Quoix 2005{published data only} Quoix E, Breton JL, Gervais R, Wilson J, Schramel F, Cardenal F, et al.A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer. Lung Cancer 2005 Aug;49(2):253-61.
18. Roth 1992{published data only} Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, et al.Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. Journal of Clinical Oncology 1992 Feb;10(2):282-91.
19. Sculier 1990{published data only} Sculier JP, Klastersky J, Libert P, Ravez P, Thiriaux J, Lecomte J, et al.A randomized study comparing etoposide and vindesine with or without cisplatin as induction therapy for small cell lung cancer. EORTC Lung Cancer Working Party. Annals of Oncology 1990;1(2):128-33.
20. Sculier 1993{published data only} Sculier JP, Paesmans M, Bureau G, Dabouis G, Libert P, Vandermoten G, et al.Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. Journal of Clinical Oncology 1993 Oct;11(10):1858-65.
21. Smith 1991{published data only} Smith AP, Anderson G, Chappell G, Bowen DR. Does the substitution of cisplatin in a standard four drug regimen improve survival in small cell carcinoma of the lung? A comparison of two chemotherapy regimens. Thorax 1991 Mar;46(3):172-4.
22. Souhami 1997{published data only} Souhami RL, Spiro SG, Rudd RM, Ruiz de Elvira MC, James LE, Gower NH, et al.Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. Journal of the National Cancer Institute 1997 Apr 16;89(8):577-80.
23. Sundstrom 2002{published data only} Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Hatlevoll R, Dahle R, et al.Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. Journal of Clinical Oncology 2002 Dec 15;20(24):4665- 72.
24. Urban 1999a{published data only} Urban T, Baleyte T, Chastang CL, Jeannin L, Delaval P, Zaegel M, et al.Standard combination versus alternating chemotherapy in small cell lung cancer: a randomised clinical trial including 394 patients. 'Petites Cellules' Group. Lung Cancer 1999 Aug;25(2):105-13.
25. Urban 1999b{published data only} Urban T, Chastang C, Lebas FX, Duhamel JP, Adam G, Darse J, et al.The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma: A randomized study of 457 patients. 'Petites Cellules' Group. Cancer 1999 Dec 1;86(11):2238-45.
26. Veronesi 1994{published data only} Veronesi A, Cartei G, Crivellari D, Magri MD, Della Valentina M, Foladore S, et al.Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer: a randomised study. European Journal of Cancer 1994;30A(10):1474-8.
27. Wampler 1991{published data only} Wampler GL, Heim WJ, Ellison NM, Ahlgren JD, Fryer JG. Comparison of cyclophosphamide, doxorubicin, and vincristine with an alternating regimen of methotrexate, etoposide, and cisplatin/ cyclophosphamide, doxorubicin, and vincristine in the treatment of extensive-disease small-cell lung carcinoma: a Mid-Atlantic Oncology Program study. Journal of Clinical Oncology 1991 Aug;9 (8):1438-45.
28. White 2001{published data only} White SC, Lorigan P, Middleton MR, Anderson H, Valle J, Summers Y, et al.Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma. Cancer 2001 Aug 1;92(3):601-8.
29. Wolf 1987{published data only} Wolf M, Havemann K, Holle R, Gropp C, Drings P, Hans K, et al.Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: amulticenter German randomized trial. Journal of Clinical Oncology 1987 Dec;5(12):1880-9.
30. Artel-Cortes 2004{published data only} Artel-Cortes A, Gomez-Codina J, Gonzalez-Larriba JL, Barneto I, Carrato A, Isla D, et al.Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer. Clinical Lung Cancer 2004 Nov;6(3):175-83.
31. Blackstock 2005{published data only} Blackstock AW, Bogart JA, Matthews C, Lovato JF, McCoy T, Livengood K, et al.Split-course versus continuous thoracic radiation therapy for limited-stage small-cell lung cancer: final report of a randomized phase III trial. Clinical Lung Cancer 2005 Mar;6(5):287-92.
32. De Marinis 2005{published data only} De Marinis F, Nelli F, Lombardo M, Ferrau F, Barbera S, Bertetto O, et al.A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma. Cancer 2005 Feb 15;103(4):772-9.
33. Eckardt 2006{published data only} Eckardt JR, von Pawel J, Papai Z, Tomova A, Tzekova V, Crofts TE, et al.Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. Journal of Clinical Oncology 2006 May 1;24(13):2044-51.
34. Hanna 2006{published data only} Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T, et al.Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. Journal of Clinical Oncology 2006 May 1;24(13):2038-43.
35. Lara 2006{published data only} Lara PN Jr, Gandara DR, Natale RB. Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer. Clinical Lung Cancer 2006 Mar;7(5):353-6.
36. McClay 2005{published data only} McClay EF, Bogart J, Herndon JE 2nd, Watson D, Evans L, Seagren SL, et al.A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235). American Journal of Clinical Oncology 2005 Feb;28(1):81-90.
37. Niell 2005{published data only} Niell HB, Herndon JE 2nd, Miller AA, Watson DM, Sandler AB, Kelly K, et al.Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. Journal of Clinical Oncology 2005 Jun 1;23(16):3752-9.
38. Paccagnella 2004{published data only} Paccagnella A, Favaretto A, Oniga F, Barbieri F, Ceresoli G, Torri W, et al.Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. Lung Cancer 2004 Jan;43(1):83-91.
39. Pathak 2005{published data only} Pathak AK, Bhutani M, Guleria R, Bal S, Mohan A, Mohanti BK, et al.Chemotherapy alone vs. chemotherapy plus high dose multiple antioxidants in patients with advanced non small cell lung cancer. Journal of the American College of Nutrition 2005 Feb;24(1):16-21.
40. Schild 2004{published data only} Schild SE, Bonner JA, Shanahan TG, Brooks BJ, Marks RS, Geyer SM, et al.Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. International Journal of Radiation, Oncology, Biology, Physics 2004 Jul 15;59(4):943-51.
41. Seifart 2005{published data only} Seifart U, Jensen K, Ukena J, Mueller C, Schroder M, Fuhr HG, et al.Randomized phase II study comparing topotecan/cisplatin administration for 5 days versus 3 days in the treatment of extensive stage small cell lung cancer (SCLC). Lung Cancer 2005 Jun;48(3):415-22.
42. Abeloff 2004 Abeloff MD. Clinical oncology. 3rd Edition. Philadelphia, Pa: Elsevier Churchill Livingstone, 2004.
43. ACN 2004 ACN. Clinical practice guidelines for the prevention, diagnosis and management of lung cancer. Clinical practice guidelines for the prevention, diagnosis and management of lung cancer. Sidney: Cancer Council Australia, 2004.
44. Berghmans 1999 Berghmans T, Paesmans M, Mascaux C. A meta-analysis of the role of etoposide (VP-16) and cisplatin (CDDP) in small cell lung cancer (SCLC) with methodology assessment. European Journal of Cancer 1999;35(Suppl 4):248.
45. Cohen 1978 Cohen EA, Mathews MJ. Small cell bronchogenic carcinoma: a distinct clinico-pathological entity. Seminars in Oncology 1978;5:234-43.
46. Doll 1978 Doll R, Peto R. Cigarette smoking and bronchial carcinoma: dose and time relationships among regular smokers and lifelong non-smokers. Journal of Epidemiology and Community Health 1978;32(4):303-13.
47. Evans 1986 Evans WK, Feld R, Murray N, Pater J, Shelley W, Willan A, et al.The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer. Seminars in Oncology Sep 1986;13(3 (Suppl 3)):10-6.
48. Ferlay 2001 Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000 Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base. 1. Lyon: International Agency for Research on Cancer, 2001, issue 5:http://www-dep.iarc. fr/.
49. Gralla 2004 Gralla RJ. Quality-of-life considerations in patients with advanced lung cancer: effect of topotecan on symptom palliation and quality of life. Oncologist 2004;9 Suppl 6:14-24.
50. Higgins 2005 Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. Chichester, UK: John Wiley & Sons. The Cochrane Collaboration.
51. Higgins 2008 Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available fromwww.cochrane-handbook.org. The Cochrane Collaboration, 2008.
52. Kato 1969 Kato Y, Fergusson TB, Bennett DE, et al.Oat cell carcinoma of the lung. A review of 13 cases. Cancer 1969;23:517- 24.
53. Lassen 1995 Lassen U, Osterlind K, Hansen M, Dombernowsky P, Bergman B, Hansen HH. Long-term survival in small cell lung cancer: posttreatment characteristics in patients surviving 5 to 18+ years - an analysis of 1714 consecutive patients. Journal of Clinical Oncology 1995;13:1215-20.
54. Le Pechoux 2004 Le Pechoux C, Dhermain F, Bretel JJ, Laplanche A, Dunant A, Tarayre M, et al.Modalities of radiotherapy in small cell lung cancer: thoracic radiotherapy and prophylactic cerebral irradiation. Revue de Pneumologie Clinique 2004;3S:91-103.
55. Miller 1981 Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981 Jan 1;47(1):207-14.
56. Peckham 1995 Peckham MJ, Pinedo HM, Veronesi U. Oxford Textbook of Oncology. Oxford University Press, 1995.
57. Pujol 2000 Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. British Journal of Cancer 2000;83(1):8-15.
58. RevMan 2008 Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
59. Rosenberg 1965 Rosenberg B, Vn Camp L, Krigas T. Inhibition of cell division in Eschericia coli by electrolysis products from a platinum electrode. Nature 1965;205:698-9.
60. Souhami 1990 Souhami RL, Law K. A report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research. British Journal of Cancer 1990;61:584-9.
61. Stahel 1989 Stahel R, Aisner J, Ginsberg R, Havemann K, Hirsch F, Ihde D, et al.Staging and prognostic factors in small cell lung cancer. Lung Cancer 1989;5:119-26.
62. van Loon 1997 van Loon AJ, Kant IJ, Swaen GM, Goldbohm RA, Kremer AM, van den Brandt PA. Occupational exposure to carcinogens and risk of lung cancer: results from The Netherlands cohort study. Occupational and Environmental Medicine 1997;54(11):817-24.
63. WHO 1979 World Health Organization. WHO handbook for reporting results of cancer treatment.. WHO offset publication no 48.. Geneva, Switzerland: World Health Organization, 1979.